COMPANY PROFILE

Syncromune

Explore full profile

A clinical stage biopharmaceutical company developing a new cancer therapy

Fort Lauderdale, United StatesFounded 2020Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2024

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Syncromune

Syncromune, Inc. is pioneering a novel approach to cancer treatment by developing next-generation intratumoral immunotherapies. These therapies are designed to harness the body's immune system to fight and eradicate metastatic cancers. The company operates in the biotechnology and healthcare market, primarily serving patients diagnosed with advanced-stage cancers. Syncromune's business model focuses on research and development, clinical trials, and eventual commercialization of its proprietary treatments. Revenue is generated through a combination of direct sales, partnerships with healthcare providers, and potential licensing agreements. The company is committed to long-term, sustained growth and aims to make significant strides in cancer treatment through continuous innovation and scientific breakthroughs.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Fort Lauderdale, United States
Employees: 57
Open positions: 9
Dealroom signal: 93.5/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Dec 2024	$100M	$400M	Wasatch Venture Partners	↗
SEEDOther financing	Nov 2022	$5.3M	$21M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Syncromune website traffic

Latest recorded traffic for Syncromune is 1.5K monthly website visits, down 16.7% over the last three months. Syncromune's team grew 32.6% over the past year.

Latest monthly visits1.5K 3-month web change-16.7% 1-year team growth+32.6%

Monthly website visitsJan 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior Manager Regulatory AffairsFort Lauderdale, FL · IOS Development · Aug 25, 2026 Associate Director, Drug Product DevelopmentFort Lauderdale, FL · Other · Aug 2, 2026 Clinical Trial Manager, ImmunologyFort Lauderdale, FL · Other · Jul 26, 2026 Senior Director of Analytical DevelopmentFort Lauderdale, FL · Business Intelligence · Jul 2, 2026 Director, Quality Assurance (Quality Systems)Fort Lauderdale, FL · Other · Jul 2, 2026 Field Engineer, OncologyFort Lauderdale, FL · Other · Jun 24, 2026

6 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAscidian TherapeuticsEnables precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time	Boston, United States	Operational	47	$90M	$250M
ATAtalanta TherapeuticsPioneering RNAi treatments for neurodegenerative diseases	Boston, United States	Operational
CTCartesian TherapeuticsCartesian \| Developing potent, safer cell and gene therapies for cancer and autoimmune diseases - Cartesian	Gaithersburg, United States	Operational
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
ETEpics TherapeuticsDrug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development	Charleroi, Belgium	Operational
LOLocanaCreating a new class of gene therapies by targeting disease-causing messenger RNA	San Diego, United States	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
THTheraBiologicsA proprietary human nsc platform for cancer treatment	United States	Operational